Altre lingue Cabaletta Bio, Inc.

Azioni

CABA

US12674W1099

Tempo reale stimato Cboe BZX Altri mercati azionari 20:19:39 26/06/2024			Variaz. 5gg	Var. 1 gen.
7,4 ^USD	+2,42%		-11,94%	-67,69%

14/06	Aggiornamento settoriale: i titoli del settore sanitario sono in ribasso prima della campanella di venerdì	MT
14/06	Aggiornamento settoriale: Assistenza sanitaria	MT

Altre lingue

Sblocca tutte le notizie: sii il primo a essere informato e reagisci prima dei mercati!

Registrazione 100% gratuita

Sector Update: Health Care Stocks Lean Lower Pre-Bell Friday	14/06
Sector Update: Health Care	14/06
Cabaletta Bio Says Autoimmune Disease Therapy Showed Promise in Early Results	14/06
Cabaletta Bio Reports Positive Initial Clinical Data from Phase 1/2 RESET-Myositis™ and RESET-SLE™ Trials of CABA-201	14/06
Cabaletta Bio Reports Positive Initial Clinical Data from Phase 1/2 RESET-Myositis™ and RESET-SLE™ Trials of CABA-201	14/06
Cabaletta Bio Reports Positive Initial Clinical Data from Phase 1/2 RESET-Myositis? and RESET-SLE? Trials of CABA-201	14/06
Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference	29/05
Cabaletta Bio : Corporate Presentation	15/05
Cabaletta Bio Reports First Quarter 2024 Financial Results and Provides Business Update	15/05
Cabaletta Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	15/05
Cabaletta Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ	13/05
Cabaletta Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ	13/05
Cabaletta Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	21/03
Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	21/03
Cabaletta Bio, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	21/03
Cabaletta Bio Gets Orphan Drug Designation From FDA For Systemic Sclerosis Treatment	20/03
Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Systemic Sclerosis	20/03
Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Systemic Sclerosis	20/03
North American Morning Briefing : Markets on Hold -2-	20/03
North American Morning Briefing : Stock Futures -2-	13/03

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Cabaletta Bio, Inc.

Azioni

CABA

US12674W1099

Altre lingue

Filtri